Results 221 to 230 of about 32,908 (264)
Some of the next articles are maybe not open access.
Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Current Pharmaceutical Design, 2010Stent thrombosis (ST) is a rare complication following coronary stenting; however given the associated serious consequences, in particular death and myocardial infarction, it remains a source of considerable concern for cardiologists. Although no differences have been found between drug-eluting stents (DES) and bare-metal stents (BMS) in terms of early
Alfonso, Ielasi +2 more
openaire +2 more sources
Single or dual antiplatelet therapy after PCI
Nature Reviews Cardiology, 2017The optimal duration and type of antiplatelet therapy after implantation of a drug-eluting stent (DES) remains uncertain. At the time of the first-in-man implantation of the sirolimus DES in 1999, the protocol-defined dual antiplatelet therapy (DAPT) duration was only 2 months.
Miyazaki, Yosuke +12 more
openaire +2 more sources
Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy
The American Journal of Cardiology, 2015Several observational studies, randomized controlled trials, and meta-analyses suggested that pretreatment with clopidogrel in addition to aspirin could reduce the rate of ischemic events, especially in the setting of acute coronary syndromes. Newer P2Y12 inhibitors like prasugrel and ticagrelor, which provide faster and stronger platelet inhibition ...
Leonardo De Luca +3 more
openaire +3 more sources
Gastrointestinal protection with dual antiplatelet therapies
BMJ, 2018Dalal and colleagues provide a concise update on the pharmacological and behavioural management of patients after a myocardial infarction.1 This otherwise holistic article does not mention the risks and means of prevention of gastrointestinal bleeding, which is associated with poorer prognosis in this patient population. Aspirin monotherapy increases
openaire +2 more sources
Dual Antiplatelet Therapy After Stent Implantation
JAMA, 2014The Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice (OPTIMIZE) trial1 contributes to the body of evidence supporting an improved safety profile of second-generation drug-eluting stents compared with first-generation models.2 However, although it is tempting to simplify the
Stephen J, Greene +2 more
openaire +2 more sources
Dual Antiplatelet Therapy in Acute Ischemic Stroke
Current Atherosclerosis Reports, 2015Stroke recurrence is common in the early period after a cerebral ischemic event. Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke and transient ischemic attack. Compared to monotherapy, dual antiplatelet therapy has more robust inhibition of platelet activation
Negar, Asdaghi, Jose G, Romano
openaire +2 more sources
Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies
Drugs, 2017Dual antiplatelet therapy (DAPT) prevents recurrent ischemic events after an acute coronary syndrome (ACS) as well as stent thrombosis (ST) in patients with prior stent implantation. Nevertheless, these benefits are counterbalanced by a significant bleeding hazard, which is directly related to the treatment duration.
Costa F, Windecker S, Valgimigli M
openaire +3 more sources
Dual antiplatelet therapy after coronary stenting
Expert Opinion on Pharmacotherapy, 2016Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the mainstay of pharmacotherapy in patients undergoing coronary stenting. Currently, three P2Y12 receptor inhibitors are approved for clinical use, including clopidogrel, prasugrel, and ticagrelor, with the latter two being preferred in patients presenting with an ...
Yongwhi, Park +3 more
openaire +2 more sources
Dual Antiplatelet Therapy or Dual Pathway Inhibition
Thrombosis and Haemostasis, 2023Shinya Goto, Shinichi Goto
openaire +2 more sources
The dual-therapy Combo Stent: A Rationale for a Light Dual Antiplatelet Therapy Treatment
Future Cardiology, 2018The COMBO stent is a new, sirolimus-eluting bioresorbable polymer, bioengineered stent. This technology combines the advantages of second-generation drug-eluting stents with the endothelial progenitor cell capture technology mediated by the anti-CD34 antibody coating on the COMBO luminal surface.
Luca, Baldetti +4 more
openaire +2 more sources